Meet Thrive: The New Kid on the Liquid Biopsy Block

There’s a new player in the liquid biopsy field. Thrive Earlier Detection Corp., announced late last month that it has launched and has raised $110 million in its Series A round. The financing is pretty sizeable. To put this in perspective, Cambridge, MA-based Thrive’s round is $10 million more than Grail’s series A round, which was raised in 2016. Liquid Biopsy companies are known for having above-average financings (In 2017, Redwood City, CA-based, Guardant Health pulled in $360 million in funding at one point ). Part of the reason for the huge funding rounds is to support the large clinical trials these companies need to evaluate their technology. Thrive is studying its CancerSEEK test in DETECT, a prospective trial in 10,000 healthy individuals underway in collaboration with Geisinger Health System. The impetus is to better understand test performance and the implementation of its findings into patient care. Thrive said it intends to conduct additional clinical studies to generate evidence to support regulatory approvals, inclusion in cancer screening guidelines and broad reimbursement. “The mission of Thrive is to bring earlier cancer detection to routine medical care,” Alexis Borisy, a member of the board of directors for Thrive, told MD+DI. “Our vision is that in your annual checkup, or once every couple of years, that Thrive will be able to detect th...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news